
J. F Seymour
Consultant or advisory role: Abbvie, Acerta Pharma, Janssen, F.
Hoffmann‐La Roche Ltd, Sunesis Pharmaceuticals, Takeda, AstraZe-
neca, Bristol‐Myers Squibb, Gilead Sciences, MEI Pharma, MorphoSys
Honoraria: Abbvie, Acerta Pharma, Janssen, F. Hoffmann‐La Roche
Ltd, Sunesis Pharmaceuticals, Takeda
Research funding: Abbvie, Celgene, Janssen, F. Hoffmann‐La
Roche Ltd
Educational grants: Abbvie, F. Hoffmann‐La Roche Ltd
Other remuneration: Speakers' bureau: Abbvie, F. Hoffmann‐La
Roche Ltd; Expert Testimony: F. Hoffmann‐La Roche Ltd
P. Corradini
Consultant or advisory role: AbbVie, ADC Therapeutics, Amgen,
Celgene, Daiichi Sankyo, Gilead, Incyte, Janssen, Kite, KyowaKirin,
Novartis, F. Hoffmann‐La Roche Ltd, Sanofi, Servier, Takeda
Honoraria: AbbVie, ADC Therapeutics, Amgen, Celgene, Daii-
chi Sankyo, Gilead, Incyte, Janssen, Jazz Pharmaceutics, Kite,
KyowaKirin, Novartis, F. Hoffmann‐La Roche Ltd, Sanofi, Servier,
Takeda
G. Gritti
Consultant or advisory role: Autolus, Gilead, IQvia, Amgen, F.
Hoffmann‐La Roche Ltd, Takeda
Honoraria: Takeda
Educational grants: F. Hoffmann‐La Roche Ltd, AbbVie, Gilead,
Janssen, Takeda
J. Hirata
Employment or leadership position: Genentech, Inc.
Stock ownership: F. Hoffmann‐La Roche Ltd
L. Musick
Employment or leadership position: Genentech, Inc.
Stock ownership: F. Hoffmann‐La Roche Ltd/GNE
S. Saha
Employment or leadership position: Genentech, Inc.
B. Croft
Employment or leadership position: Genentech, Inc.
Stock ownership: Genentech, Inc./F. Hoffmann‐La Roche Ltd
C. Flowers
Consultant or advisory role: Abbvie, Bayer, BeiGene, Celgene,
Denovo Biopharma, Genentech/Roche, Gilead, Karyopharm, Phar-
macyclics/Janssen, Spectrum
Research funding: 4D, Abbvie, Acerta, Adaptimmune, Allogene,
Amgen, Bayer, Celgene, Cellectis, EMD, Gilead, Genentech/Roche,
Guardant, Iovance, Janssen Pharmaceutical, Kite, Morphosys, Nektar,
Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics,
Xencor, Ziopharm, Burroughs Wellcome Fund, Eastern Cooperative
Oncology Group, National Cancer Institute, V Foundation, Cancer
Prevention and Research Institute of Texas: CPRIT Scholar in Cancer
Research
112 |CHRONOS‐3: RANDOMIZED PHASE III STUDY OF
COPANLISIB PLUS RITUXIMAB VS RITUXIMAB/PLACEBO IN
RELAPSED INDOLENT NON‐HODGKIN LYMPHOMA (INHL)
P. L. Zinzani
1
, M. Capra
2
, M. Özcan
3
, F. Lv
4
, W. Li
5
, E. Yañez
6
, K.
Sapunarova
7
, T. Lin
8
, J. Jin
9
, W. Jurczak
10
, A. Hamed
11
, M.‐C. Wang
12
,
R. Baker
13
, I. Bondarenko
14
, Q. Zhang
15
, J. Feng
16
, K. Geissler
17
, M.
Lazaroiu
18
, G. Saydam
19
, Á. Szomor
20
, K. Bouabdallah
21
, R. Galiulin
22
,
T. Uchida
23
, L. Mongay Soler
24
, A. Cao
25
, F. Hiemeyer
26
, A. Mehra
27
,
B. H. Childs
28
, Y. Shi
29
, M. J. Matasar
30
1
IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Emato-
logia “Seràgnoli”; Università di Bologna, Dipartimento di Medicina Spe-
cialistica, Diagnostica e Sperimentale, Bologna, Italy,
2
Hospital Mãe de
Deus, Centro de Hematologia e Oncologia, Porto Alegre, Brazil,
3
Ankara
University School of Medicine, Hematology Department, Ankara, Turkey,
4
Fudan University Shanghai Cancer Center, Department of Medical
Oncology, Shanghai, China,
5
The First Hospital of Jilin University,
Department of Hematology, Changchun, China,
6
University of La Fron-
tera, Department of Internal Medicine, Oncology‐Hematology Unit,
Temuco, Chile,
7
Medical University, Department of Internal Medicine,
Hematology Division, Plovdiv, Bulgaria,
8
Sun Yat‐sen University Cancer
Center, Department of Medical Oncology, Guangzhou, China,
9
The First
Affiliated Hospital of Zhejiang University College of Medicine, Department
of Hematology, Hangzhou, China,
10
Maria Skłodowska‐Curie National
Research Institute of Oncology, Department of Clinical Oncology, Krakow,
Poland,
11
Petz Aladár Megyei Oktató Kórház, Hematológiai Osztály, Gyor,
Hungary,
12
Chang Gung Memorial Hospital Kaohsiung, Department of
Medicine, Kaohsiung, Taiwan,
13
Perth Blood Institute, Murdoch Univer-
sity, Western Australia Centre for Thrombosis and Haemostasis, Perth,
Australia,
14
City Dnipropetrovsk Multi‐field Clinical Hospital, 4 DSMA,
Chemotherapy Department, Dnipro, Ukraine,
15
Harbin Medical Univer-
sity, Cancer Hospital, Department of Medical Oncology, Harbin, China,
16
Jiangsu Cancer Hospital, Department of Medical Oncology, Nanjing,
China,
17
Sigmund Freud University, 5th Medical Department with He-
matology, Oncology and Palliative Medicine, Vienna, Austria,
18
S.C. Poli-
clinica de Diagnostic Rapid S.A., Department of Hematology, Brasov,
Romania,
19
Ege Üniversitesi Tıp Fakültesi, Division of Hematology, Izmir,
Turkey,
20
Pécsi Tudományegyetem Klinikai Központ, 1st Department of
Internal Medicine, Pécs, Hungary,
21
University Hospital of Bordeaux,
Hematology and Cellular Therapy Department, Bordeaux, France,
22
Clinical Oncological Dispensary of Omsk Region, Department of
Chemotherapy for Children and Adults, Omsk, Russian Federation,
23
Japanese Red Cross Nagoya Daini Hospital, Department of Hematology
and Oncology, Nagoya, Japan,
24
Bayer HealthCare Pharmaceuticals, Inc.,
Clinical Development, Whippany, USA,
25
Bayer HealthCare Pharmaceu-
ticals, Inc., Clinical Statistics, Whippany, USA,
26
Pharmaceuticals Division,
Bayer AG, Clinical Statistics, Berlin, Germany,
27
Bayer HealthCare Phar-
maceuticals, Inc., Clinical Development, Whippany, USA,
28
Bayer
HealthCare Pharmaceuticals, Inc., Clinical Development, Whippany, USA,
29
National Cancer Center/National Clinical Research Center for Cancer/
Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union
Medical College, Department of Medical Oncology, Beijing, China,
SUPPLEMENT ABSTRACTS
-
171